SerbinCommunications

(805) 963-0439 | Toll-Free (800) 876-6425

www.serbin.com LA / NY / UK

Cognition Studio, Inc.

The PI3K delta pathway 

Prev Next
Previous

CAL-101/GS-1101 and the PI3K Delta Pathway

medical illustration of Gilead Sciences, a leader in developing innovative oral medicines targeting PI3K Delta with a focus on B-cell malignancies, including NHL and CLL uses solutions like this to describe the PI3K pathway in a format that is easy to convey and understand while being visually compelling. Only a portion of the overall image is shown here due to space constraints. Created in Illustrator with finishing touches in Photoshop.
Next medical illustration of This series serves as a visual platform for our client to give a primer on human toll-like receptors 1-10, with a focus on TLR8. Shown here are the left and middle pathways. Target audience is investor-centric.
Platform is PPT, web, and corporate fact sheets. Created in Illustrator with finishing touches in Photoshop.

Human TLR Family Series

Gilead Sciences, a leader in developing innovative oral medicines targeting PI3K Delta with a focus on B-cell malignancies, including NHL and CLL uses solutions like this to describe the PI3K pathway in a format that is easy to convey and understand while being visually compelling. Only a portion of the overall image is shown here due to space constraints. Created in Illustrator with finishing touches in Photoshop.

Keywords: Color, Design, Line with Color, Advertising / Marketing, Education, Allergy / Immunology, Biotechnology, Disease Management, Molecular Biology, Pharmacology

© 2011, Gilead Science